Libido & Sexual-Health Peptides

“Libido peptides” sounds like a product category. It isn’t, really — not the way “weight-loss peptides” or “growth-hormone peptides” are. It’s one genuinely approved drug surrounded by a handful of investigational and gray-market compounds that get swept into the same marketing bucket. Understanding which is which is the single most useful thing you can take away from this page, because the gap between the approved member and everything else is enormous.

This guide maps the whole class: what each compound is, what the evidence actually supports, and how US access works in 2026. For the deep dives — mechanism, the specific indication, access routes — we link out to dedicated pages. Here, the goal is orientation.

The shape of this category: one approved drug, a lot of hype

Start with the honest summary. There is exactly one FDA-approved peptide for a sexual-health indication: bremelanotide, better known as PT-141 and sold under the brand name Vyleesi. The FDA approved it in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). That’s the entire approved category.

Everything else you’ll see described as a “libido peptide” — kisspeptin, Melanotan-2, oxytocin formulations, various blends sold by research-chemical vendors — is either investigational, repurposed off-label, or obtained gray-market. None of them carries an FDA approval for sexual health, and the evidence behind them ranges from early to essentially anecdotal.

This matters because the marketing rarely makes the distinction. A vendor selling a peptide vial and a licensed pharmacy filling a Vyleesi prescription are doing two completely different things, with completely different evidence, oversight, and legal standing behind them. Lumping them together as “peptides for libido” hides exactly the information you need to make a sensible decision.

Note: This page is educational. It does not sell, supply, or prescribe anything, and it deliberately avoids dosing instructions. Sexual-health concerns deserve a real evaluation by a licensed provider, not a self-experiment with an unregulated injectable.

The distinction that sorts everything: desire vs performance

Before the individual compounds, one concept makes the whole category legible: sexual desire and sexual performance are different problems, treated in different places in the body.

Desire (libido) is centrally driven — it originates in the brain. The melanocortin system in the hypothalamus is one of the circuits involved, and that’s the system PT-141 acts on. A “desire” drug is trying to turn up motivation and interest.

Performance (arousal, erection) is largely a peripheral, mechanical matter of blood flow. The familiar drugs here — sildenafil (Viagra), tadalafil (Cialis), and the rest of the PDE5 inhibitor class — relax blood vessels so blood reaches the genitals. Crucially, these are not peptides at all — they’re small-molecule drugs. They get mentioned in the same breath as PT-141 because both touch sexual function, but they work in different places by different mechanisms.

The practical upshot: a desire-targeting peptide won’t solve a blood-flow problem, and a blood-flow drug won’t fix low desire. People who confuse the two end up disappointed by a compound that was never designed to address their actual issue. If you’re unsure which problem you have, that’s a conversation for a clinician — and a useful one, because the answer changes what (if anything) is worth trying.

PT-141 (bremelanotide): the one FDA-approved member

PT-141 is the anchor of this category and the only member with real regulatory standing. It’s a melanocortin-receptor agonist that activates MC3R and MC4R circuits in the brain to increase sexual desire — a central mechanism, not a blood-flow one.

As Vyleesi, it’s approved specifically for premenopausal women with acquired, generalized HSDD — meaning a loss of desire that wasn’t there before and isn’t explained by another condition, medication, or relationship issue. It’s delivered as an on-demand subcutaneous autoinjector, taken ahead of anticipated activity rather than daily, with the regimen set by the prescriber per the approved label.

A few things worth knowing at the category level:

• The evidence is real but modest. The Phase 3 program (the RECONNECT trials) met its endpoints, but the average improvement in desire was on the smaller side, and nausea was common. PT-141 is a legitimate option for the right patient, not a transformative one.
• Its approval is narrow. Use in men, or in postmenopausal women, is off-label — the approved channel doesn’t cover them. Some telehealth providers prescribe compounded bremelanotide off-label, which is a clinician’s judgment call, not an approved use.
• It has a genuine safety gate. Bremelanotide transiently raises blood pressure, so it isn’t appropriate for people with uncontrolled hypertension or significant cardiovascular disease. That screen is part of why this should go through a provider.

For the full picture, see our dedicated pages on what PT-141 is, PT-141 for libido, PT-141 for women with HSDD, its side effects, and how access works in the US.

Kisspeptin: upstream, investigational, and stalled at the FDA

Kisspeptin is the compound most often floated as “the next libido peptide,” and it’s worth understanding why that framing is premature.

Kisspeptin is a naturally occurring peptide that sits high in the reproductive hormone axis — it’s an upstream signal that helps trigger the release of the hormones governing reproduction. Research groups have studied it for its effects on sexual processing in the brain, which is the basis for the libido marketing. The science is genuinely interesting, but it’s early, mostly confined to research settings, and a long way from an approved indication.

On the regulatory side, kisspeptin-10’s path is effectively stalled. An FDA advisory committee reviewed it for compounding in late 2024, and the FDA’s analysis recommended against adding it to the 503A bulks list, citing inadequate safety and efficacy evidence. It was not among the peptides the FDA moved to review at its July 2026 advisory meeting. So as of 2026, kisspeptin is an investigational research compound — not an approved drug and not a peptide a compliant pharmacy is positioned to supply for sexual health.

Melanotan-2: where PT-141 came from — and why it’s not a shortcut

There’s a neat piece of history here: PT-141 was discovered as a side effect of Melanotan-2 research. Melanotan-2 (MT-2) is a synthetic melanocortin agonist developed as a tanning compound, and researchers noticed it consistently produced sexual arousal in study participants. That observation led to bremelanotide. So MT-2 genuinely does affect libido — through the same melanocortin family of receptors.

That history gets used to sell MT-2 as a cheaper, vial-based “libido peptide.” It’s a bad trade. MT-2 is not FDA-approved, is obtained gray-market, and carries documented safety concerns — its melanocortin activity drives skin darkening and new or changing moles, plus nausea and blood-pressure effects, and the gray-market supply means unknown concentration and purity on top of that. The targeted, screened, approved version of this mechanism already exists as PT-141; using the unregulated tanning precursor for the same effect adds risk without adding benefit.

On status: MT-2 was among the peptides the FDA removed from its restricted Category 2 in April 2026, but that’s not approval — it’s slated for a later advisory review, and nothing about its standing as a safe, supervised therapy has changed. We cover this in detail on what Melanotan-2 is, and we don’t recommend it for sexual health.

Oxytocin and the “intimacy” peptides

Oxytocin — the “bonding hormone” — turns up in this category too, usually as a compounded nasal spray marketed for intimacy, connection, or arousal. It’s a real peptide hormone with an approved injectable form used in obstetrics for entirely different purposes. But the evidence that intranasal oxytocin meaningfully improves sexual function or desire is thin and inconsistent. It’s best understood as an experimental wellness product, not an established sexual-health treatment. Treat the marketing claims with skepticism and the compounded sourcing with the same caution as any other gray-market peptide.

What isn’t a peptide (and gets sold as one)

Because the category is loosely defined in marketing, a few things commonly land in the “libido peptide” bucket that don’t belong there:

• PDE5 inhibitors — sildenafil, tadalafil, and similar. These are the standard, approved erectile-dysfunction drugs, but they’re small molecules, not peptides, and they target blood flow rather than desire.
• Testosterone and other hormones. Low libido is sometimes hormonal, and testosterone therapy is a real medical intervention — but it’s a hormone, not a peptide, and it requires its own workup and monitoring.
• Herbal “blends” and supplements sold alongside peptides. These aren’t peptides and aren’t regulated as drugs; efficacy claims are usually unsupported.

Knowing what’s actually in the bottle — and what mechanism it targets — is half the battle in this space.

Where US access stands in 2026

The access picture splits cleanly along the approved/unapproved line.

Vyleesi (PT-141) is a legal, FDA-approved prescription drug. For its approved indication, a licensed provider evaluates the patient and writes a prescription a specialty pharmacy fills. Off-label use (men, postmenopausal women, compounded versions) happens through telehealth at a provider’s discretion, with the usual caveat that compounded products don’t carry the approved drug’s full oversight.

Everything else sits in the broader, unsettled peptide-compounding landscape. In 2026 that landscape is genuinely in motion: the FDA removed roughly a dozen peptides from its restricted Category 2 in April, and it has advisory-committee reviews scheduled to consider whether some should be eligible for compounding. But — and this is the part the headlines blur — removal from Category 2 is not approval, not Category 1 placement, and not authorization to compound. The formal rulemaking is still pending, and the libido-adjacent compounds (kisspeptin, MT-2) are either not on the active review docket or were previously reviewed unfavorably. So the practical status of most “libido peptides” sold by research-only vendors remains a legal gray area.

This is current as of the date above and is changing month to month; treat any specific compound’s status as provisional and verify it before acting. See are peptides FDA-approved? and are peptides legal in the US? for the fuller regulatory rundown.

What to discuss with a provider

If low desire or sexual difficulty is the actual concern, the most useful step isn’t picking a peptide — it’s getting the problem characterized. A few things worth raising with a clinician:

• Which problem is it? Desire, arousal, performance, or a mix — because that determines whether any peptide is even the right category, or whether a PDE5 inhibitor, hormone evaluation, or non-drug approach fits better.
• What’s driving it? Medications (antidepressants are a common culprit), thyroid or hormone issues, sleep, stress, and relationship factors all affect libido and are often more fixable than people expect.
• Is PT-141 appropriate and safe for you? Specifically the cardiovascular screen, and whether your situation matches the approved indication or would be off-label.
• What’s the source? A pharmacy-filled prescription and a research-vendor vial are not the same product. If a compound is involved, ask where it’s compounded and under what oversight.

The honest takeaway for this whole category: one approved drug, narrowly indicated and modestly effective, plus a lot of investigational and gray-market compounds riding its coattails. That’s not a reason to dismiss the field — it’s a reason to approach it with clear eyes and a real provider.